Comparative Pharmacology
Head-to-head clinical analysis: ENSKYCE versus VIORELE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENSKYCE versus VIORELE.
ENSKYCE vs VIORELE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.
VIORELE is a monoclonal antibody that binds to and inhibits the activity of interleukin-17A (IL-17A), a pro-inflammatory cytokine involved in the pathogenesis of plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle
50 mg orally once daily
None Documented
None Documented
12 hours (terminal); allows once-daily dosing in most patients
Terminal elimination half-life of 12–15 hours (mean 13.5 h) in healthy adults; may be prolonged in renal impairment (up to 30 h).
Renal: ~70% unchanged; Biliary/Fecal: ~20% as metabolites
Primarily renal (unchanged drug and metabolites, ~60%) and fecal (~30%), with minor biliary contribution (~10%).
Category C
Category C
Oral Contraceptive
Oral Contraceptive